12/18/2007   DURECT Announces Positive ELADUR™ Phase IIa Study Results
12/06/2007   Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy™
12/04/2007   DURECT to Present at Upcoming Conferences
11/20/2007   DURECT TO PRESENT AT PIPER JAFFRAY HEALTHCARE CONFERENCE
11/01/2007   DURECT Corporation Announces Third Quarter 2007 Financial Results
11/01/2007   DURECT to Present at Upcoming Conferences
10/31/2007   DURECT Corporation Invites You to Join Its Third Quarter 2007 Earnings Conference Call
10/17/2007   DURECT to Host Webcast in Conjunction with an Analyst’s Day on October 17
09/26/2007   DURECT To Present At UBS Global Life Sciences Conference
09/11/2007   DURECT To Present At Merriman Curhan Ford’s Annual Investor Summit
08/31/2007   DURECT Corporation To Present At The NewsMakers In The Biotech Industry Investment Conference
08/07/2007   DURECT Corporation Announces Second Quarter 2007 Financial Results
07/31/2007   DURECT Corporation Invites You to Join Its Second Quarter 2007 Earnings Conference Call on the Web
07/17/2007   DURECT Reports Positive Results from POSIDUR™ Phase IIb Hernia Trial, Triggering $8 million Milestone Payment from Nycomed
07/11/2007   Patient Recruitment Completed for Pivotal Phase III Study of Remoxy™
06/27/2007   DURECT Announces the Initiation of Sufentanil Patch Phase II Study by Endo Pharmaceuticals
06/21/2007   DURECT Corporation Presenting at the Jefferies Healthcare Conference
06/11/2007   DURECT Corporation Presenting at the Sixth Annual Needham Biotechnology and Medical Technology Conference
05/17/2007   DURECT Provides an Update to the Memryte™ Program Under Development by Voyager Pharmaceutical Corp
05/08/2007   DURECT Corporation Presenting at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
05/07/2007   DURECT Corporation Announces First Quarter 2007 Financial Results
05/01/2007   DURECT Corporation Presenting at the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference
04/30/2007   DURECT Corporation Invites You to Join Its First Quarter 2007 Earnings Conference Call on the Web
04/09/2007   DURECT Corporation Presenting at the CIBC Biotechnology & Specialty Pharmaceuticals Conference
02/28/2007   DURECT Corporation to Participate in Upcoming Healthcare Conferences
02/12/2007   DURECT Corporation Presenting at the BIO CEO and Investor Conference
02/08/2007   DURECT Corporation Announces Fourth Quarter and Year End 2006 Financial Results
02/05/2007   DURECT Establishes Corium as Manufacturer of TRANSDUR™-Bupivacaine
01/30/2007   DURECT Corporation Invites You to Join its Fourth Quarter and Year-End 2006 Conference Call on the Web
01/29/2007   DURECT Signs POSIDUR™ Manufacturing Agreement with Hospira
01/24/2007   DURECT Amends Agreement with Voyager Governing Memryte™
01/03/2007   DURECT Starts Phase II Dosing for TRANSDUR™-Bupivacaine (DUR-843)
12/18/2006   DURECT Corporation Appoints Dr. Terrence F. Blaschke to its Board of Directors
12/11/2006   DURECT Corporation Announces Positive Phase I Study Results with New Product in Development
11/30/2006   Positive Phase I Results Reported for DURECT’s Second Abuse-Resistant Opioid Pain Medicine
11/29/2006   DURECT and Nycomed Sign $202 Million Agreement to Develop and Commercialize POSIDUR™ in Europe and Other Select Countries
11/03/2006   DURECT Corporation Announces Third Quarter 2006 Financial Results
10/31/2006   DURECT Corporation to Present at Upcoming Conferences
10/27/2006   DURECT Corporation Invites You to Join its Third Quarter 2006 Conference Call on the Web
10/19/2006   DURECT Provides an Update to the Memryte™ Program Under Development by Voyager Pharmaceutical Corp.
10/16/2006   DURECT Corporation Presenting at BIO InvestorForum 2006
09/21/2006   DURECT Corporation Presenting at the UBS Global Life Sciences Conference
09/12/2006   DURECT Corporation Appoints Matthew J. Hogan as Chief Financial Officer
08/04/2006   DURECT Corporation Presenting at the Securities Research Associates Technology Conference
08/02/2006   ORADUR(TM) Technology Milestone: New ORADUR-based Investigational Drug Candidate Commences Phase I Clinical Program
07/27/2006   DURECT Corporation Announces Second Quarter 2006 Financial Results
07/19/2006   DURECT Corporation Invites You to Join its Second Quarter 2006 Conference Call on the Web
07/10/2006   DURECT Corporation to Present at Upcoming Life Sciences Conferences
06/23/2006   DURECT Corporation Presenting at the Jefferies Life Sciences Conference
06/12/2006   DURECT Corporation Presenting at the Needham & Company Fifth Annual Biotechnology and Medical Technology Conference
05/12/2006   DURECT Corporation Presenting at the Rodman & Renshaw 3rd Annual Global Healthcare Conference
05/05/2006   ORADUR™ Technology Milestone: Remoxy™ (ORADUR-based oxycodone) Commences Pivotal Phase III Program
05/02/2006   DURECT Corporation Appoints Peter Langecker Chief Medical Officer
05/02/2006   DURECT Corporation Announces First Quarter 2006 Financial Results
04/27/2006   DURECT Provides An Update On Its Post-Operative Pain Depot (SABER™-Bupivacaine) Program
04/25/2006   DURECT Corporation Invites You to Join its First Quarter 2006 Conference Call on the Web
04/19/2006   DURECT Corporation Presenting at the UBS Global Specialty Pharmaceuticals Conference
03/30/2006   DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
02/17/2006   ORADUR™ Technology Milestone: Remoxy™ (ORADUR-based oxycodone) Receives Special Protocol Assessment and Commences Pivotal Phase III
02/10/2006   DURECT Corporation Presenting at the BIO CEO and Investor Conference
02/08/2006   DURECT Corporation Announces Anticipated Development Program Milestones for Fiscal Year 2006
02/08/2006   DURECT Corporation Reports Fourth Quarter and Year End 2005 Financial Results
01/26/2006   DURECT to Expand Clinical Program to Additional Surgical Procedures and to Initiate U.S. Clinical Studies and for its Post-Operative Pain Relief Depot
01/23/2006   DURECT Corporation Invites You to Join its Fourth Quarter and Year-End 2005 Conference Call on the Web
01/06/2006   DURECT Announces Promotions and Management Changes
01/03/2006   DURECT Corporation Presenting at the JPMorgan 24th Annual Healthcare Conference
12/26/2005   DURECT Announces Positive Preliminary Results from Transdermal Sufentanil Patch Study in Patients
11/11/2005   DURECT Highlights Major Commercial Strategic Alliance for ORADUR™ Sustained Release Oral Gel-cap Technology
11/04/2005   DURECT Corporation Presenting at the Sixteenth Annual CIBC Healthcare Conference
11/03/2005   DURECT Corporation Presenting at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference
11/02/2005   DURECT Corporation Announces Pricing of Public Offering
10/27/2005   DURECT Corporation Announces Proposed Public Offering of Common Stock
10/18/2005   DURECT Announces Positive Preliminary Results from its Phase II Study for its Post-Operative Pain Relief Depot
10/14/2005   DURECT Corporation Announces Initiation of Dosing for Phase III Clinical Program for Memryte (DURIN™-Leuprolide Implant) Program Under Development with Voyager Pharmaceuticals
10/13/2005   DURECT Corporation Announces Third Quarter 2005 Financial Results
10/07/2005   DURECT Corporation Invites You to Join its Third Quarter 2005 Conference Call on the Web
09/21/2005   DURECT To Present Preliminary Phase II Clinical Data for Cohort 3 for its Post-Operative Pain Relief Depot at American College of Surgeons Conference
09/19/2005   DURECT Corporation Announces Completion of Dosing in Cohort 3 of its Phase II Study for its Post-Operative Pain Relief Depot
09/09/2005   DURECT Corporation Announces Positive Phase III Clinical Results for Remoxy, a Novel Oral Pain Medication using the ORADUR™ Gel-Cap
08/08/2005   DURECT Corporation Presenting at Summer Tech Fest 2005 Investor Conference Hosted by C.E. Unterberg Towbin and Security Research Associates
08/01/2005   DURECT Corporation Presenting at the Adams Harkness & Hill Annual Summer Seminar
07/22/2005   DURECT Plans to Reduce Convertible Debt Balance by $5 Million
07/22/2005   DURECT Corporation Announces Second Quarter 2005 Financial Results
07/12/2005   DURECT Corporation Presenting at the C. E. Unterberg, Towbin Emerging Growth Conference
07/11/2005   DURECT Announces Start of Dosing in Cohort 3 of its Phase II Study for its Post-Operative Pain Relief Depot
07/08/2005   DURECT Corporation Invites You to Join its Second Quarter 2005 Conference Call on the Web
06/20/2005   DURECT Announces Preliminary Results from Cohort 2 of its On-Going Phase II Study for its Post-Operative Pain Relief Depot
05/24/2005   DURECT Corporation Presenting at the Friedman Billings Ramsey 9th Annual Growth Investor Conference
05/03/2005   DURECT Corporation Announces First Quarter 2005 Financial Results and Update on Its Development Programs
04/19/2005   DURECT Corporation Invites You to Join its First Quarter 2005 Conference Call on the Web
04/18/2005   Simon X. Benito Appointed to the Board of Directors of DURECT Corporation to Replace Albert L. Zesiger
04/11/2005   DURECT Corporation Announces Planned Departure of CFO and Director Thomas A. Schreck
03/29/2005   DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
03/14/2005   DURECT Corporation And Endo Pharmaceuticals Sign Agreement To Develop And Commercialize DURECT’s Seven-Day Transdermal Pain Patch
02/24/2005   DURECT Corporation to Present at the Security Research Associates' Spring Technology & Life Sciences Investor Conference
02/16/2005   DURECT Initiates Phase II Program for Its Sufentanil Patch Product
02/10/2005   DURECT Completes Dosing of the Phase I Pharmacokinetic Study for Its Sufentanil Patch Product and of the First Cohort of the Phase II Study for Its Post-Operative Pain Relief Depot
02/10/2005   DURECT Corporation Reports Fourth Quarter and Year End 2004 Financial Results
01/28/2005   DURECT Corporation Announces Completion of Clinical Trial Enrollment for DURIN™-Based Leuprolide Product Candidate
01/25/2005   DURECT Names Dr. Paula Mendenhall Senior Vice President of Operations
01/20/2005   DURECT Corporation Invites You to Join its Fourth Quarter and Year-End 2004 Conference Call on the Web
01/12/2005   DURECT Corporation Publishes Development Program Milestones for Fiscal Year 2005
01/05/2005   DURECT Corporation Presents an Update to Its Development Pipeline and Hosts 1st Analyst Luncheon
12/23/2004   DURECT Corporation Announces Initiation of Phase III Studies for Remoxy, a Novel Oral Pain Medication using the ORADUR™ Gel-Cap
12/20/2004   DURECT and Voyager Pharmaceutical Announce the Acceptance of DURIN™ Investigational New Drug Application and Clinical Protocol by the FDA for the Treatment of Alzheimer’s Disease
11/22/2004   DURECT Corporation Presenting at the Lazard 1st Annual Life Sciences Conference
11/04/2004   DURECT Corporation Presenting at the Fifteenth Annual CIBC Healthcare Conference
10/25/2004   DURECT Corporation Announces Third Quarter 2004 Financial Results and Update on Its Development Programs
10/25/2004   DURECT Initiates Phase II Clinical Program for Post-Operative Pain Relief Depot
10/22/2004   DURECT Corporation Presenting at the C. E. Unterberg, Towbin Specialty Pharmaceutical Conference
10/22/2004   DURECT Initiates Phase I Trial for Its Proprietary Transdermal Sufentanil Patch
10/21/2004   DURECT Corporation Presenting at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference
10/18/2004   DURECT Corporation Invites You to Join its Third Quarter 2004 Conference Call on the Web
10/12/2004   DURECT Corporation Presenting at the HealthpointCapital Biomaterials Summit
10/05/2004   DURECT Corporation Presenting at BIO Emerging Company Investor Forum
09/16/2004   DURECT Corporation Presenting at the First Annual Merriman Curhan Ford & Co. Investor Summit
08/09/2004   DURECT Corporation Presenting at the Halpern Capital Summer Growth Stock Conference
08/02/2004   DURECT Corporation Presenting at the Adams Harkness & Hill’s 24th Summer Seminar
07/21/2004   DURECT Corporation Announces Second Quarter 2004 Financial Results and Update on Its Development Programs
07/15/2004   DURECT Corporation Invites You to Join its Second Quarter 2004 Conference Call on the Web
07/06/2004   DURECT ANNOUNCES POSITIVE CLINICAL RESULTS WITH ITS ORADUR™ SUSTAINED RELEASE ORAL GEL-CAP TECHNOLOGY
06/21/2004   DURECT Corporation and NeuroSystec Corporation Announce Exclusive Agreement to Develop Treatments for Certain Inner Ear Disorders Including Tinnitus
05/06/2004   DURECT Corporation Presenting at the Rodman & Renshaw Healthcare Conference
04/27/2004   DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
04/22/2004   DURECT Corporation Announces First Quarter 2004 Financial Results
04/14/2004   DURECT Corporation Invites You to Join its First Quarter 2004 Conference Call on the Web
03/23/2004   Michael D. Casey Appointed to the Board of Directors of DURECT Corporation
02/24/2004   DURECT Corporation Presenting at the 4th Annual Smith Barney Citigroup Specialty Pharmaceuticals Conference
02/13/2004   DURECT Announces Promotions and Management Changes
02/10/2004   DURECT Corporation Reports Fourth Quarter 2003 and Year End Financial Results
01/27/2004   DURECT Corporation Invites You to Join its Fourth Quarter and Year End 2003 Conference Call on the Web
01/06/2004   DURECT Corporation Presenting at the JPMorgan H&Q 22nd Annual Healthcare Conference
11/07/2003   DURECT Corporation Presenting at The CIBC World Markets 14th Annual Healthcare Conference
11/06/2003   DURECT Announces Positive Clinical Results for its Post-operative Pain Relief Depot using the SABER™ Delivery System
11/06/2003   DURECT Corporation Announces Third Quarter 2003 Financial Results
10/20/2003   DURECT Corporation Invites You to Join its Third Quarter 2003 Conference Call on the Web
10/16/2003   DURECT Announces Update to CHRONOGESIC Program
10/09/2003   DURECT Initiates Manufacture of Clinical Product for its CHRONOGESIC® (sufentanil) Pain Therapy Product
09/23/2003   Jon S. Saxe Appointed to the Board of Directors of DURECT Corporation
09/03/2003   DURECT Corporation Presenting at the Thomas Weisel Partners Healthcare Conference
09/02/2003   DURECT Corporation Completes Validation of Terminal Sterilization Manufacturing Process for its CHRONOGESIC (sufentanil) Pain Therapy Product
08/05/2003   DURECT Corporation Presenting at the Adams Harkness & Hill’s 23rd Summer Seminar
07/24/2003   DURECT Corporation Announces Second Quarter 2003 Financial Results
07/11/2003   Initial Purchaser Exercises Option to Purchase an Additional $10 Million of the $50 Million of 6.25% Convertible Notes
07/11/2003   DURECT Corporation Invites You to Join its Second Quarter 2003 Conference Call on the Web
06/13/2003   DURECT Corporation Announces Pricing of $50 Million Convertible Note Offering
06/11/2003   DURECT Corporation Announces Proposed $50 Million Convertible Debt Offering
06/10/2003   DURECT Initiates Human Clinical Testing for its Post-operative Pain Relief Depot using the SABER™ Delivery System
05/15/2003   DURECT Corporation Presenting at Friedman Billings Ramsey 7th Annual Technology & Growth Investor Conference
04/28/2003   DURECT Corporation Presenting at The CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
04/28/2003   DURECT CORPORATION ANNOUNCES FIRST QUARTER 2003 FINANCIAL RESULTS
04/15/2003   DURECT Corporation Invites You to Join its First Quarter 2003 Conference Call on the Web
01/28/2003   DURECT Corporation Reports Fourth Quarter 2002 and Year End Financial Results
01/15/2003   DURECT Corporation Invites You to Join its Fourth Quarter and Year End 2002 Conference Call on the Web
01/14/2003   Pain Therapeutics And DURECT Corporation Announce Exclusive Agreement To Formulate Certain Long-Acting Opioid Drugs
01/02/2003   DURECT Corporation Presenting at the JPMorgan H&Q 21st Annual Healthcare Conference
12/27/2002   David R. Hoffmann Appointed to the Board of Directors of DURECT Corporation
11/22/2002   DURECT Corporation Increases Focus on Product Development Activities and Reducing Costs
11/19/2002   BioPartners and DURECT Corporation Enter into Agreement for Development of Sustained Release Interferon alpha
11/14/2002   DURECT Corporation and Thorn BioScience LLC Expand Existing Licensing Agreement to Develop Veterinary Products
11/12/2002   DURECT Corporation and ALZA Corporation Amend Licensing Agreement
11/12/2002   DURECT Corporation Reports Third Quarter 2002 Financial Results
11/11/2002   DURECT Corporation Postpones Its Third Quarter 2002 Conference Call
11/11/2002   Endo Pharmaceuticals and DURECT Corporation Agree To Collaborate on Treatment in Pain Management
10/30/2002   DURECT Corporation Presenting at The CIBC World Markets 13th Annual Health Care Conference
10/16/2002   DURECT Corporation Invites You to Join its Third Quarter 2002 Conference Call on the Web
10/04/2002   DURECT Corporation Presenting at The UBS Warburg Global Life Sciences Conference
08/26/2002   DURECT Corporation Delays Enrolling Additional Patients in its Phase III Clinical Trial for CHRONOGESIC Pending Clinical Trial Protocol Amendments
08/08/2002   DURECT Corporation Presenting at The Adams, Harkness & Hill’s 22nd Annual Summer Seminar
07/29/2002   DURECT Corporation and Voyager Pharmaceutical Corporation Sign Development and Commercialization Agreement to Develop Treatment for Alzheimer's Disease
07/29/2002   DURECT Corporation Reports Second Quarter 2002 Financial Results
07/09/2002   DURECT Initiates Pivotal Phase III Program for the CHRONOGESIC™ (sufentanil) Pain Therapy System
07/08/2002   DURECT Corporation Invites You to Join its Second Quarter 2002 Conference Call on the Web
06/11/2002   DURECT Corporation to Present at the Goldman Sachs Twenty - Third Annual Global Healthcare Conference
06/05/2002   DURECT Corporation Presenting at the UBS Warburg Global Specialty Pharmaceuticals Conference
04/29/2002   DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
04/24/2002   DURECT Corporation Reports First Quarter 2002 Financial Results
04/08/2002   DURECT Corporation Invites You to Join its First Quarter 2002 Conference Call on the Web
04/02/2002   DURECT Corporation Files IND for the Long Term Treatment of Asthma
03/27/2002   DURECT Corporation and Cardinal Health Announce Collaboration to Research and Develop Long Acting Gel-Cap Products Using The SABER™ Delivery System
03/18/2002   DURECT Corporation Announces Positive Results of Pilot Phase III Study For The CHRONOGESIC™ Product
01/30/2002   DURECT Corporation Reports Fourth Quarter 2001 and Year End Financial Results
01/23/2002   DURECT Corporation Sponsors Symposium on Novel Drug Delivery Technologies at the 45th Annual Meeting of the Western Pharmacology Society (WPS)
01/14/2002   DURECT Corporation Invites You to Join its Fourth Quarter and Year End 2001 Conference Call on the Web
01/04/2002   DURECT Corporation Presenting at the JPMorgan H&Q 20th Annual Healthcare Conference
11/16/2001   Janssen Pharmaceutica Enters into Exclusive Marketing Discussions with DURECT Corporation for Chronogesic™
11/01/2001   DURECT Corporation Presenting at the CIBC World Markets Twelfth Annual Health Care Conference
11/01/2001   DURECT Corporation Reports Initiation of Phase III Program for Chronogesic™
10/31/2001   DURECT Corporation Reports Third Quarter 2001 Financial Results
10/25/2001   DURECT Announces Results From Research Collaboration with the University of Maastricht Showing Blood Flow to the Ischemic Heart Restored Following Local Administration of Growth Factors
10/16/2001   DURECT Corporation Presenting at the Techvest 3rd Annual Healthcare Conference
10/15/2001   DURECT Corporation Invites You to Join its Third Quarter 2001 Conference Call on the Web
09/24/2001   DURECT Corporation Announces Promotions of Officers
09/05/2001   DURECT Announces Positive Phase II Results on Chronogesic™ for Long-Term Pain Relief
08/24/2001   DURECT Corporation Invites You to Join its Phase II Trial Results Conference Call on the Web
07/30/2001   DURECT Corporation Reports Second Quarter 2001 Financial Results
07/19/2001   DURECT Corporation Invites You to Join its Second Quarter 2001 Conference Call on the Web
07/06/2001   DURECT Corporation Adopts Stockholder Rights Plan
06/29/2001   DURECT Announces Chronogesic™ Preliminary Clinical Results of Phase II Trial
06/25/2001   DURECT Announces Filing of Special 510(k) Application for its New Generation IntraEAR® Ear Catheter Product And Approval of Physician Sponsored Investigational New Drug Application for Treatment of Meniere’s Disease
05/24/2001   DURECT Completes Construction of Commercial Manufacturing Facility
05/11/2001   DURECT Corporation Completes the Clinical Portion of Phase II Clinical Trial for DUROS Sufentanil
04/30/2001   DURECT Corporation Reports First Quarter 2001 Financial Results
04/30/2001   DURECT Corporation Announces Acquisition of Southern BioSystems, Inc.
04/24/2001   DURECT Corporation Invites You to Join its First Quarter 2001 Conference Call on the Web
04/03/2001   Dennis M. Fisher, MD Named Vice President for Medical Affairs
03/27/2001   DURECT Corporation Announces Long-Term Drug Supply Agreement with Mallinckrodt
03/09/2001   DURECT Corporation Announces Completion of Patient Enrollment in Phase II Clinical Trial for DUROS Sufentanil
03/01/2001   Armand P. Neukermans Appointed to the Board of Directors of DURECT Corporation
03/01/2001   DURECT Corporation Invites You to View Its Salomon Smith Barney Specialty Pharmaceuticals Conference Investor Presentation
02/16/2001   DURECT Corporation Announces Earnings and Reports Strong Progress on Its Business
02/07/2001   DURECT Announces Acceleration of Completion of Patient Enrollment in its Phase II Clinical Trial for DUROS® Sufentanil
01/24/2001   Evelyn R. Robledo Named Vice President of Quality Assurance and Compliance
01/22/2001   DURECT Corporation Invites You to Join its Fourth Quarter Conference Call on the Web
12/11/2000   DURECT Corporation Enrolls Patients in Phase II Clinical Trial for DUROS® Sufentanil
11/13/2000   DURECT Corporation Reports Third Quarter 2000 Financial Results
11/07/2000   DURECT Corporation Invites You to Join its Third Quarter Conference Call on the Web
11/02/2000   DURECT Corporation Announces Exercise of Over-allotment Option in Initial Public Offering
10/23/2000   DURECT Corporation Announces Commencement of Construction of Commercial Manufacturing Facility in Cupertino, CA
09/28/2000   DURECT Announces Initial Public Offering
04/20/2000   DURECT Announces Filing of Registration Statement
10/06/1999   DURECT Corporation Acquires IntraEAR, Inc.
08/12/1999   Genetronics Announces Election of Dr. Felix Theeuwes, A Drug Delivery Pioneer, to Its Board of Directors
08/02/1999   DURECT Corporation Receives $20 Million in Second Round of Funding


 
 © 2000-2008 DURECT Corporation
Last updated: September 30, 2008
Search     Contact     Site Index     Legal Notice     Privacy Policy